<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000600470"><TermName>CT-322</TermName><TermDefinition><DefinitionText>A substance being studied in the treatment of cancer. CT-322 may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor and a type of antiangiogenesis agent. Also called Angiocept and VEGFR-2 inhibitor CT-322.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><SpanishTermName>CT-322</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer. CT-322 podría prevenir la formación de vasos sanguíneos nuevos que los tumores necesitan para crecer y podría destruir células cancerosas. Es un tipo de inhibidor del receptor del factor de crecimiento endotelial vascular-2 (RFCEV-2) y un tipo de antiangiogénico. También se llama Angiocept y inhibidor del RFCEV-2 CT-322.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-07-14</DateFirstPublished><DateLastModified>2009-04-21</DateLastModified></GlossaryTerm>
